aTYR PHARMA INC (ATYR) Form 8-K — May 15, 2026
aTyr Pharma reported a net loss of $10.8 million for the first quarter of 2026, a significant improvement from the $14.9 million loss in the same period last year, driven by reduced R&D spending of $7.3 million. The company ended the quarter with $68.3 million in cash and investments, providing a runway to advance its clinical programs without immediate dilution. Following a Type C meeting with the FDA, aTyr announced a clear path forward for its lead candidate efzofitimod in pulmonary sarcoidosis.
Key figures
- Total Assets
- 79654000
- Cash Position
- 68318000
- Ga Expenses
- 4119000
- Rd Expenses
- 7317000
- Shares Outstanding
- 98043839
- Phase2 Enrollment Target
- 25
- Planned Phase3 Enrollment
- 372
Price after filing
Close on the filing date to close N calendar days later (from $0.56). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.